AtriCure, Inc. (ATRC) Stock Price
ATRCStock
$56.07+50.56%52W
Market Cap$2.85B
P/E—
PEG Ratio10.00
Div yield—
Beta1.24
ATRC Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)80.81%
Price vs S&P 500 (4W)-2.53%
PEG Ratio10.00
VGM Score58.85
ATRC Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.02 | $0.18 | +650.31%(+$0.16) | |
| Q1 2026 | -$0.06 | $0.00 | +100.00%(+$0.06) | |
| Q4 2025 | -$0.04 | $0.06 | +249.89%(+$0.10) | |
| Q3 2025 | -$0.12 | -$0.01 | +91.49%(+$0.11) | |
| Q2 2025 | -$0.16 | -$0.02 | +87.71%(+$0.14) |
ATRC Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.06
4.06
4.06
4.06
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
ATRCAtriCure, Inc. | D | B | A | 5.0x | 20.9% | 76.3% | 2.3% | $56.07 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
About AtriCure, Inc.
AtriCure develops surgical solutions for treating atrial fibrillation, managing left atrial appendage, and alleviating post-operative pain in cardiac and thoracic procedures. Its product portfolio includes cryoablation, radiofrequency ablation, and nerve pain management technologies used in open-heart and minimally invasive surgical settings. The company sells through direct sales and distributors, with the majority of revenue from the United States.